Peripheral quantitative computed tomography in the assessment of bone mineral density in anti-TNF-treated rheumatoid arthritis and ankylosing spondylitis patients

Table 2 Significant correlations of QCT BMD parameters with DXA BMD and laboratory parameters, as well as disease activity in the full RA+AS cohort^a

	QTOTBMD-0	QTOTBMD-12	QTRABBMD-0	QTRABBMD-12	QCORTBMD-0	QCORTBMD-12
Disease activity
DAS28/BASDAI-0	NS	NS	R=-0.402 p=0.015	NS	NS	R=-0.465 p=0.005
DXA parameters
DXL2L4BMD-0	R=0.399 p=0.016	NS	R=0.437 p=0.008	NS	NS	R=0.493 p=0.004
DXL2L4BMD-12	R=0.406 p=0.014	NS	R=0.436 p=0.008	NS	NS	R=0.501 p=0.004
DXFEMBMD-0	NS	NS	NS	NS	NS	R=0.563 p=0.001
DXFEMBMD-12	NS	R=0.402 p=0.014	NS	NS	NS	R=0.547 p=0.001
Bone biochemical markers
CTX-12	NS	NS	R=0.400 p=0.011	NS	NS	NS

^aBonferroni’s correction was applied in order to exclude the effects of multiple comparisons. Therefore in this case p<0.017 is considered statistically significant
Abbreviations: BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BMD bone mineral density, CATHK cathepsin K, CTX C-terminal telopeptide, DAS28 28-joint disease-acitivity score, DXFEMBMD DXA femoral neck BMD, DXL2L4BMD DXA lumbar 2-4 vertebral BMD, NS non-significant, OC osteocalcin, P1NP procollagen type I N-propeptide, QCORTBMD QCT cortical bone mineral density, QTOTBMD QCT total bone mineral density, QTRABBMD QCT trabecular bone mineral density, RANKL Receptor Activator of Nuclear κB Ligand

ISSN: 1471-2474